November 3, 2017 / 10:13 AM / a year ago

BUZZ-Valeant: FDA gives surprise nod to potential blockbuster eye drop

** US-listed shares of Canadian drugmaker rise 6.9 pct to $11.81 in premarket trade

** Co on Thursday said FDA approved its glaucoma drug latanoprostene bunod, which will be marketed as Vyzulta

** FDA has previously rejected the eye drop twice, citing problems with the company’s Florida manufacturing facility

** “We think this could be a blockbuster drug for VRX, and the Street was not expecting approval until 2018+,” Cantor Fitzgerald’s Louise Chen says

** Up to Thursday’s close, stock had fallen 23.8 pct this year (Reporting by Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below